The final conversation of Episode 16 explores possible possible pathways and treatment strategies for NASH therapy in a future world with multiple classes of agents.
Mazen Noureddin and Stephen Harrison discuss future directions cost-effectiveness research in and outside the U.S. might take, while the Surfers consider the implications.
Mazen Noureddin describes how he became engaged in studying the cost-effectiveness of widespread NASH screening for diabetics in the US, and what he has found, while the Surfers comment on the value of this pivotal work.
Mazen Noureddin joins the Surfers to discuss his work determining the cost-effectiveness of non-invasive NASH testing and treatment in Type 2 diabetics and the broader population. The discussion shifts to considering broader treatment issues.
Manal Abdelmalek and Ian Rowe join Roger, Louise and Donna to review the morning that Vlad Ratziu and Michael Charlton both identified as the highlight session of NASH-TAG 2021.
The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.
Wayne Eskridge describes some of the opportunities and concerns that affect diabetic patients might experience as they learn about NASH and the liver issues related to diabetes.
Jörn Schattenberg reviews modes of action for GLP-1 agonists and SGLT-2 inhibitors and discusses the data that exist in NAFLD and NASH
Jörn Schattenberg and Fatty Liver Foundation President Wayne Eskridge join Louise and Roger to consider the current and future roles that GLP-1 receptor agonists like semaglutide and SGLT-2 inhibitors like Jardiance in treating NASH patients.
Three experience NASH trial site execs identify at least 11 specific things to consider when designing your trial protocols
